College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

NATIONAL PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Xylazine GNRC 20 mg/ml oplossing voor injectie voor runderen, paarden, honden en katten

Created:
November 2023

PRODUCT SUMMARY

Authorisation number	REG NL 131451
Name, strength and pharmaceutical form	Xylazine GNRC 20 mg/ml oplossing voor injectie voor runderen, paarden, honden en katten
Applicant	Alfasan Nederland BV Kuipersweg 9 3449 JA Woerden The Netherlands
Active substance(s)	Xylazine
ATC vetcode	QN05CM92
Target species	Cattle, horses, dogs and cats
Indication for use	In cattle, horses, dogs and cats: -sedation; -premedication in combination with an anaesthetic.

PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

SUMMARY OF ASSESSMENT

Legal basis of original application*	Application in accordance with Article 18 of Regulation (EC) 2019/6 as amended.
Reference product (RP)	Rompun
Marketing authorisation holder	Bayer B.V. Animal Health Division
MS where the RP is or has been authorised	The marketing authorisation has been withdrawn in the Netherlands on 27 September 2010
Marketing authorisation number	REG NL 5409
Date of authorisation	The product was authorised in the ninety's in the Netherlands.
Date of completion of the original national procedure	30 November 2023
Date veterinary medicinal product first authorised in the Reference Member State (MRP only)	Not applicable.
Concerned Member States for original procedure	Not applicable.
Concerned Member States for subsequent recognition procedure	Not applicable.

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of referenceability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the reactions observed are indicated in the SPC.

The VMP is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

2. QUALITY DOCUMENTATION (physicochemical, biological or microbiological information)

A. Product description

The VMP contains 20 mg/ml xylazine (as hydrochloride) and the following excipients: benzethonium chloride and water for injection; sodium hydroxide, hydrochloric acid may be used for pH adjustment.

The product is packed in clear type II glass vials of 30 ml, fitted with bromobutyl rubber stoppers and aluminium caps.

The VMP is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Description of the manufacturing method

The VMP is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

The VMP is manufactured using conventional manufacturing techniques. Process validation results for three smallest production batches have been provided. The tests performed during production are described.

A post-authorisation commitment has been provided to validate the manufacturing process on batches of the maximum size of the proposed range

Regarding the sterilisation methods of the glass vials and the rubber stoppers additional information has been provided.

C. Production and control of starting materials

The active substance is xylazine hydrochloride, an established substance described in the European Pharmacopeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

A certificate of suitability (CEP) for xylazine hydrochloride is available in the file.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification should be provided.

The excipients are in conformity with Ph.Eur. requirements. No excipients are within the scope of the TSE Guideline present or used in the manufacture of this product.

The glass vials and stoppers are in conformity with the Ph.Eur. requirements

D. Control tests carried out on isolated intermediates during the manufacturing process

Not applicable.

E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification and their limits have been justified and are considered appropriate to adequately control the quality of the VMP.

Suitable validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site demonstrating compliance with the specification.

F. Stability tests

As mentioned on the Certificate of Suitability Stability the active substance the retest period of the active substance is 3 years when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the VMP throughout its shelf life when stored under the approved conditions.

An in-use shelf-life of 28 days has been supported by appropriate data and is considered acceptable.

G. Other information

Not applicable.

3. SAFETY DOCUMENTATION (safety and residues tests)

A. Safety tests

User safety

This is a generic application. The proposed warnings and safety measures are in line with the CVMP conclusion concerning alpha2-adrenoreceptor agonist (EMEA/681319/2008) and include warnings to avoid accidental injection, skin, eye or mucosal contact. Also, the risk for pregnant women has been included. The safety warnings are adequate to mitigate the risk for the user.

Environmental Risk Assessment

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the VMP will be used to treat a small number of animals in a flock or herd.

B. Residues documentation

Residue tests

This is a generic application. The product has the same qualitative and quantitative composition in active substance as its reference product. Bioequivalence has been demonstrated. For horse the product is to be administered intravenously. The withdrawal period for horse as applicable for the reference product, can therefore be adopted for this generic application, i.e. 1 days for meat. The product is not authorized for use in mares producing milk for human consumption.

For cattle, the product has to be administered intramuscularly as well as intravenously. It is justified that the small differences in composition when compared to the reference do not significantly impact depletion of residues from the injection site. Therefore, the withdrawal period established for the reference product, i.e. 1 day for meat and zero days for milk can also be adopted for cattle.

4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this VMP are equivalent to those of the reference VMP.

5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.

POST-AUTHORISATION PROCEDURES

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the VMP. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes, which have been made after the original procedure, which are important for the quality, safety or efficacy of the VMP.

None.